Ursula A. Matulonis, MD, discussued studies are being conducted assessing the use of mirvetuximab soravtansine in patients with folate receptor-α–positive platinum-resistant ovarian cancer.
Approval Alert | Mirvetuximab Soravtansine Folate Receptor-α-Positive Platinum-Resistant Ovarian Cancer
Ursula A. Matulonis, MD, indicated that acknowledgement of external targets such as FR-α could lead to success with antibody-drug conjugates in platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, spoke about the phase 3 SORAYA trial and how it helped lead to the approval of mirvetuximab soravtansine in folate receptor-α–positive platinum-resistant ovarian cancer.
The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.
Advertisement
Advertisement
Trending on CancerNetwork
1
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
5
